European CHMP recommends license extension of venetoclax (Venclyxto) for newly diagnosed acute myeloid leukaemia

The proposed licence extension is in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy.

Source:

European Medicines Agency